These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 10490835

  • 21. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 22. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.
    Sewell JM, Smyth JF, Langdon SP.
    Exp Cell Res; 2005 Mar 10; 304(1):305-16. PubMed ID: 15707595
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
    Hwang MS, Yum YN, Joo JH, Kim S, Lee KK, Gee SW, Kang HI, Kim OH.
    Anticancer Res; 2001 Mar 10; 21(4A):2649-55. PubMed ID: 11724334
    [Abstract] [Full Text] [Related]

  • 24. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE.
    Oncogene; 1999 Jun 10; 18(23):3440-51. PubMed ID: 10376522
    [Abstract] [Full Text] [Related]

  • 25. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
    Warrenfeltz SW, Lott SA, Palmer TM, Gray JC, Puett D.
    Mol Cancer Res; 2008 Nov 10; 6(11):1775-85. PubMed ID: 19010824
    [Abstract] [Full Text] [Related]

  • 26. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells.
    Yokozaki H, Budillon A, Tortora G, Meissner S, Beaucage SL, Miki K, Cho-Chung YS.
    Cancer Res; 1993 Feb 15; 53(4):868-72. PubMed ID: 8428367
    [Abstract] [Full Text] [Related]

  • 27. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D.
    Cancer Res; 2006 Apr 01; 66(7):3903-11. PubMed ID: 16585219
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
    Wu CJ, Chen Z, Ullrich A, Greene MI, O'Rourke DM.
    Oncogene; 2000 Aug 17; 19(35):3999-4010. PubMed ID: 10962556
    [Abstract] [Full Text] [Related]

  • 29. Essential role for G proteins in prostate cancer cell growth and signaling.
    Kue PF, Daaka Y.
    J Urol; 2000 Dec 17; 164(6):2162-7. PubMed ID: 11061948
    [Abstract] [Full Text] [Related]

  • 30. Experimental gene therapy of human colon cancer.
    Bold RJ, Warren RE, Ishizuka J, Cho-Chung YS, Townsend CM, Thompson JC.
    Surgery; 1994 Aug 17; 116(2):189-95; discussion 195-6. PubMed ID: 8047985
    [Abstract] [Full Text] [Related]

  • 31. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
    Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, Kanadaswam C, Lee MT.
    Anticancer Res; 2002 Aug 17; 22(3):1615-27. PubMed ID: 12168845
    [Abstract] [Full Text] [Related]

  • 32. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
    Liu SM, Carpenter G.
    J Cell Physiol; 1993 Nov 17; 157(2):237-42. PubMed ID: 7901224
    [Abstract] [Full Text] [Related]

  • 33. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.
    Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y, Kaneki M.
    Oncogene; 2006 Jan 12; 25(2):176-85. PubMed ID: 16170353
    [Abstract] [Full Text] [Related]

  • 34. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
    Nesterova M, Cho-Chung YS.
    Antisense Nucleic Acid Drug Dev; 2000 Dec 12; 10(6):423-33. PubMed ID: 11198926
    [Abstract] [Full Text] [Related]

  • 35. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.
    Oncogene; 1998 Mar 12; 16(10):1249-58. PubMed ID: 9546426
    [Abstract] [Full Text] [Related]

  • 36. Proliferative signal transduction by epidermal growth factor (EGF) in the human salivary gland adenocarcinoma (HSG) cell line.
    Sato N, Kyakumoto S, Sawano K, Ota M.
    Biochem Mol Biol Int; 1996 Mar 12; 38(3):597-606. PubMed ID: 8829620
    [Abstract] [Full Text] [Related]

  • 37. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation.
    Leung EL, Wong JC, Johlfs MG, Tsang BK, Fiscus RR.
    Mol Cancer Res; 2010 Apr 12; 8(4):578-91. PubMed ID: 20371672
    [Abstract] [Full Text] [Related]

  • 38. Type II protein kinase A up-regulation is sufficient to induce growth inhibition in SK-N-SH human neuroblastoma cells.
    Kim SN, Lee GR, Hwang ES, Lee JH, Park SD, Cho-Chung YS, Hong SH.
    Biochem Biophys Res Commun; 1997 Mar 17; 232(2):469-73. PubMed ID: 9125203
    [Abstract] [Full Text] [Related]

  • 39. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
    Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y.
    EMBO J; 1996 Jan 15; 15(2):254-64. PubMed ID: 8617201
    [Abstract] [Full Text] [Related]

  • 40. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
    Graus-Porta D, Beerli RR, Daly JM, Hynes NE.
    EMBO J; 1997 Apr 01; 16(7):1647-55. PubMed ID: 9130710
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.